Drug Trial Radar · NCT00328380
Prevention of Travelers' Diarrhea in Subjects Traveling Outside the U.S.
Last checked: Nov 20, 2026Latest source record: Nov 25, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
660
Planned (sponsor's estimate)
Start
Dec 2005
Primary completion
Dec 2006
Study completion Sep 2008
Sponsor
- Lead sponsor
- Bausch Health Americas, Inc.Industry
- Sponsor type
- Industry
- First posted
- May 19, 2006
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double
- Primary purpose
- Prevention
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The primary objective of this study is to assess the safety and tolerability of rifaximin 600 mg (3 x 200-mg tablets) once daily compared with placebo when taken for 14 days by healthy subjects to prevent travelers' diarrhea (TD) from all causes.
Conditions
- Diarrhea
Interventions
RifaximinDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- The primary endpoint in this study is the assessment of safety and tolerability of rifaximin 600 mg QD compared to placebo.
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Sunshine Medical Center
South Miami, Florida
Southwest Doctors, PA
Houston, Texas
La Porte Family Clinic
La Porte, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.